Ivabradine Accord

Active Ingredient:: Ivabradine
Origin:: EU

Ivabradine Accord (Ivabradine)

Q: What is Ivabradine Accord used for?

Ivabradine Accord contains ivabradine, an If channel inhibitor that is prescribed to lower heart rate in adults with chronic stable angina and in patients with heart failure with reduced ejection fraction, helping to improve symptoms and exercise capacity.

Q: How does ivabradine work?

Ivabradine selectively blocks the funny (If) current in the sinoatrial node by binding to HCN channels. This slows the spontaneous depolarisation of pacemaker cells, resulting in a reduction of heart rate without affecting contractility or blood pressure.

Q: What is the usual dose of Ivabradine Accord?

The dose of ivabradine is individualized by the prescribing clinician based on the patient’s heart‑rate, clinical condition, and tolerance. The prescriber determines the appropriate strength, frequency and any necessary adjustments.

Q: Is Ivabradine Accord safe in pregnancy or breastfeeding?

Safety data for ivabradine in pregnancy and lactation are limited. It should only be used when the potential benefit to the mother outweighs any possible risk to the fetus or infant, and under close medical supervision.

Q: How do I order Ivabradine Accord from GNH India?

To request Ivabradine Accord, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Q: How does ivabradine compare with beta‑blockers?

Both ivabradine and beta‑blockers lower heart rate, but ivabradine acts selectively on the If current without affecting myocardial contractility or blood pressure, whereas beta‑blockers have broader adrenergic effects. Choice depends on the patient’s clinical profile, tolerance and co‑existing conditions.

Q: What are the storage requirements for Ivabradine Accord?

Ivabradine Accord tablets should be stored at ambient temperature, below 25 °C. Keep them in the original packaging, protect from moisture and light, and store out of reach of children.

Q: How is Ivabradine Accord administered?

Ivabradine Accord is taken orally, usually with or without food, as directed by the prescriber. The tablets should be swallowed whole with a glass of water and not chewed or crushed.

Q: What are the most serious risks associated with ivabradine?

Serious risks include severe bradycardia, atrial fibrillation, symptomatic hypotension, heart block, and rare persistent visual disturbances. Patients should be educated to report any dizziness, fainting, palpitations or visual changes promptly.

Q: Who should not use Ivabradine Accord?

Ivabradine is contraindicated in patients with a resting heart rate below 60 bpm, those with acute decompensated heart failure, severe hypotension, sick sinus syndrome, or in individuals taking strong CYP3A4 inhibitors that cannot be discontinued.

Ivabradine, the active ingredient in Ivabradine Accord, is an If channel inhibitor presented as an oral tablet for oral use. It reduces heart rate by selectively inhibiting the funny current in the sinoatrial node and is indicated for chronic stable angina and heart failure with reduced ejection fraction in adult patients.

GNH India supplies Ivabradine Accord as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable logistics for global distribution.

Manufacturer / TM Owner

Accord Healthcare S.L.U.

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

Ivabradine acts on cardiac chronotropy by selectively inhibiting the If current, and is used in the following clinical settings:

Chronic stable angina: improves exercise tolerance and reduces frequency of angina attacks.
Heart failure with reduced ejection fraction: lowers heart rate to improve ventricular filling and symptoms.
Coronary artery disease where heart‑rate reduction is desired: helps control myocardial oxygen demand.

How It Works

Ivabradine selectively binds to the HCN (hyperpolarization‑activated cyclic nucleotide‑gated) channels that generate the funny (If) current in the sinoatrial node. By inhibiting this current, the drug slows spontaneous depolarization, leading to a reduction in heart rate without affecting myocardial contractility or blood pressure.

Side Effects

Ivabradine may cause a range of adverse reactions. Monitoring for side effects is part of routine clinical care.

Common Side Effects

Luminous phenomena (phosphenes): transient visual disturbances.
Bradycardia: resting heart rate below 50 bpm.
Headache.
Dizziness.
Fatigue.
Blurred vision.

Serious or Rare Side Effects

Severe bradycardia requiring medical intervention.
Atrial fibrillation or other arrhythmias.
Symptomatic hypotension.
Visual disturbances persisting beyond transient episodes.
Heart block.
Severe allergic reaction (anaphylaxis).

Precautions & Warnings

Before initiating ivabradine, clinicians should consider several safety aspects.

Cardiac monitoring: obtain baseline ECG and heart‑rate assessment.
Bradycardia risk: avoid use in patients with resting heart rate <60 bpm.
CYP3A4 inhibitors: dose adjustment may be required when co‑administered.
Pregnancy and lactation: use only if potential benefit justifies the risk.
Renal/hepatic impairment: start with lower dose and monitor closely.
Store at ambient temperature: keep in the original container, protect from moisture and light.

Avoid Interactions

Ivabradine can interact with several medicines; awareness helps prevent adverse events.

Major Interactions (Avoid)

Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may markedly increase ivabradine plasma levels.
Concomitant bradycardic agents (e.g., beta‑blockers, diltiazem): can cause excessive heart‑rate reduction.
Other If channel inhibitors: additive effect on heart‑rate control.

Moderate Interactions (Monitor Closely):\n- Moderate CYP3A4 inhibitors (e.g., fluconazole): may modestly raise ivabradine concentrations.

Drugs that prolong QT interval: increase risk of cardiac arrhythmias.
Antihypertensive agents: may enhance blood‑pressure lowering effect.

Frequently Asked Questions

Ivabradine Accord contains ivabradine, an If channel inhibitor that is prescribed to lower heart rate in adults with chronic stable angina and in patients with heart failure with reduced ejection fraction, helping to improve symptoms and exercise capacity.

Ivabradine selectively blocks the funny (If) current in the sinoatrial node by binding to HCN channels. This slows the spontaneous depolarisation of pacemaker cells, resulting in a reduction of heart rate without affecting contractility or blood pressure.

The dose of ivabradine is individualized by the prescribing clinician based on the patient’s heart‑rate, clinical condition, and tolerance. The prescriber determines the appropriate strength, frequency and any necessary adjustments.

Safety data for ivabradine in pregnancy and lactation are limited. It should only be used when the potential benefit to the mother outweighs any possible risk to the fetus or infant, and under close medical supervision.

To request Ivabradine Accord, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Both ivabradine and beta‑blockers lower heart rate, but ivabradine acts selectively on the If current without affecting myocardial contractility or blood pressure, whereas beta‑blockers have broader adrenergic effects. Choice depends on the patient’s clinical profile, tolerance and co‑existing conditions.

Ivabradine Accord tablets should be stored at ambient temperature, below 25 °C. Keep them in the original packaging, protect from moisture and light, and store out of reach of children.

Ivabradine Accord is taken orally, usually with or without food, as directed by the prescriber. The tablets should be swallowed whole with a glass of water and not chewed or crushed.

Serious risks include severe bradycardia, atrial fibrillation, symptomatic hypotension, heart block, and rare persistent visual disturbances. Patients should be educated to report any dizziness, fainting, palpitations or visual changes promptly.

Ivabradine is contraindicated in patients with a resting heart rate below 60 bpm, those with acute decompensated heart failure, severe hypotension, sick sinus syndrome, or in individuals taking strong CYP3A4 inhibitors that cannot be discontinued.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated: 14 Aug 2026

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.